ABOUT

Zhaoke Ophthalmology Limited

Zhaoke Ophthalmology Limited operates as an ophthalmic pharmaceutical company in Hong Kong, Mainland China, South Korea, and internationally. The company develops Cyclosporine A ophthalmic gel for the treatment of dry eye disease (DED); RGN-259, an eye drop indicated for moderate-to-severe DED; CsA/rebamipide ophthalmic gel for anti-inflammation and tear film stabilization; and IC-265 in Phase II clinical trial for the treatment of allergic conjunctivitis. It also engages in the development of NVK-002, an ophthalmic solution to control or slow myopia progression in children and adolescents; BRIMOCHOL PF and Carbachol PF pupil-modulating eye drops to correct for the loss of near vision associated with presbyopia; TAB014, a clinical-stage bevacizumab-based antibody indicated for wAMD; and PAN-90806 a drug indicated in the treatment of wAMD and DME. In addition, the company develops ZK002, a protein with a novel mechanism of action to contain inflammation and vascular flood leakage; Bimatoprost, a generic drug used in the treatment of glaucoma; Levobetaxolol HCl, a generic eye drop used in the treatment of glaucoma to lower pressure in the eye; and Travoprost, a prescribed PGAs for open-angle glaucoma. Further, it is involved in the development of Bimatoprost Timolol for targeting glaucoma; Latanoprost Timolol, a PGA and ß blocker combination eye drop targeting glaucoma; Travoprost Timolol, a potential first-to-market generic travoprost timolol; and Latanoprost, a prescribed PGAs for open-angle glaucoma. The company was formerly known as China Ophthalmology Focus Limited. Zhaoke Ophthalmology Limited was incorporated in 2017 and is headquartered in Guangzhou, the People's Republic of China.

Learn More

Earnings

Valuation

Cash Flow

Profitability

Performance